Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis

Published:2020-03 Issue:2 Volume:21 Page:106-113.e5
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Raphael Jacques,Batra Anupam,Boldt Gabriel^ORCID,Shah Prakesh S.,Blanchette Phillip,Rodrigues George,Vincent Mark D.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Facts & Figures, 2018,2018

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

2. Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study;European Journal of Cancer Care;2024-03-19

3. Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration;The Oncologist;2023-06-19

4. Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer;Translational Lung Cancer Research;2023-06

5. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity;Cancer Research;2023-05-19